medmix AG Cash Flow Conversion Efficiency
medmix AG cash flow conversion efficiency. Based on the latest financial reports, medmix AG (MEDX) has a cash flow conversion efficiency ratio of 0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF37.40 Million ≈ $47.28 Million USD) by net assets (CHF432.80 Million ≈ $547.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of medmix AG (2018–2025)
Cash flow conversion efficiency of medmix AG from 2018 to 2025. This chart illustrates how medmix AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MEDX stock price for real-time trading data and today's change.
medmix AG Cash Flow Conversion Ratio Explained
medmix AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
medmix AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of medmix AG ranked by their cash flow conversion efficiency. Also see medmix AG (MEDX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CapsoVision, Inc. Common Stock
NASDAQ:CV
|
-0.638x |
|
Lanpec Technologies Ltd
SHG:601798
|
0.027x |
|
Bank Bukopin Tbk
JK:BBKP
|
-0.331x |
|
Jing Jin Electric Technologies Co Ltd
SHG:688280
|
0.340x |
|
Third Point Investors Limited
LSE:TPOU
|
-0.004x |
|
Atria Oyj A
HE:ATRAV
|
-0.010x |
|
Annil Co Ltd
SHE:002875
|
-0.002x |
|
Focus Minerals Ltd
AU:FML
|
0.372x |
Annual Cash Flow Conversion Efficiency for medmix AG (2018–2025)
The table below shows the annual cash flow conversion efficiency of medmix AG from 2018 to 2025. Review medmix AG free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF432.80 Million ≈ $547.18 Million |
CHF67.80 Million ≈ $85.72 Million |
0.157x | -19.19% |
| 2024-12-31 | CHF446.70 Million ≈ $564.75 Million |
CHF86.60 Million ≈ $109.49 Million |
0.194x | +63.94% |
| 2023-12-31 | CHF474.40 Million ≈ $599.77 Million |
CHF56.10 Million ≈ $70.93 Million |
0.118x | +25.41% |
| 2022-12-31 | CHF504.80 Million ≈ $638.20 Million |
CHF47.60 Million ≈ $60.18 Million |
0.094x | -42.33% |
| 2021-12-31 | CHF533.90 Million ≈ $674.99 Million |
CHF87.30 Million ≈ $110.37 Million |
0.164x | +7.74% |
| 2020-12-31 | CHF333.40 Million ≈ $421.51 Million |
CHF50.60 Million ≈ $63.97 Million |
0.152x | -49.73% |
| 2019-12-31 | CHF295.10 Million ≈ $373.09 Million |
CHF89.10 Million ≈ $112.65 Million |
0.302x | +8.88% |
| 2018-12-31 | CHF339.70 Million ≈ $429.47 Million |
CHF94.20 Million ≈ $119.09 Million |
0.277x | -- |
About medmix AG
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for pros… Read more